Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had not previously received MS disease-modifying therapies. Participants had monthly laboratory tests and comprehensive testing every 3 months.
Epistemonikos ID: 430c465a4d2fa57dc5ac394ad073d46a3ce1cc9a
First added on: Oct 03, 2014